Immunomodulation

NanoDendrixTM can be chemically modified to modulate the innate immune response in biological systems. Depending on the type of modification, NanoDendrixTM can either increase or decrease the interferon response by upregulating or downregulating interferon stimulated genes (ISGs). At Glysantis we are investigating the use of modified NanoDendrixTM in modulating the innate immune response in vitro and in vivo for various biological applications:

Immunosuppressive NanoDendrixTM:

Current Glysantis R&D activities are investigating the use of immunosuppressive NanoDendrixTM in the following application(s):

  • Virus production: Many viruses are produced in mammalian cell culture on a large scale for the purpose of manufacturing vaccines and viral vectors for cancer and gene therapy. Experiments in Dr. Stephanie DeWitte-Orr’s lab have shown that immunosuppressive NanoDendrixTM can increase the yields of cell-culture derived viruses by dampening the in vitro interferon response. Follow-up experiments have shown applicability in a broad range of viruses and cell lines. Increasing virus yields can reduce the cost of vaccine manufacturing and viral vector production, making vaccines and novel virotherapies more accessible to developing economies.
  • Auto-immune diseases are systemic or organ-specific disorders that arise as a result of an immune system attacking the body’s own tissue. This typically occurs when adaptive immune cells (like T cells and B cells) develop autoreactivity towards self-antigens. This mechanism is typically kept in control by the innate immune system. However, under special conditions, the activation of innate immune cells in the absence of a pathogenic infection can cause the breakdown of control mechanisms that prevent the formation of adaptive auto-reactive immune cells, thereby resulting in autoimmune disease. Glysantis is investigating the use of immunosuppressive NanoDendrixTM in downregulating innate immune signaling pathways that ultimately lead to autoimmune disorders.

Immunostimulatory NanoDendrixTM:

Current Glysantis R&D activities are investigating the use of immunostimulatory NanoDendrixTM in the following application(s):

  • Vaccine adjuvants for human and animal use: Adjuvants are compounds that are delivered in combination with vaccines to increase immunogenicity and efficacy. Synthetic vaccine adjuvants have been discontinued from clinical use due to safety concerns but oil-in-water adjuvants continue to be used to this day. Glysantis is exploring the use of immunostimulatory NanoDendrixTM as a safe, biodegradable vaccine adjuvant to enhance the immunogenicity of vaccines for human and animal health.
  • Applications in Immuno-Oncology: Recent research has highlighted the role of the innate immune system in activating anti-tumor immune responses mediated by natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs). Glysantis is exploring the use of immunostimulatory NanoDendrixTM in activating anti-tumor immune responses. This research could lead to applications in combination therapy against certain types of cancer.